Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 83

1.

Recent clinical failures in Parkinson's disease with apoptosis inhibitors underline the need for a paradigm shift in drug discovery for neurodegenerative diseases.

Waldmeier P, Bozyczko-Coyne D, Williams M, Vaught JL.

Biochem Pharmacol. 2006 Nov 15;72(10):1197-206. Epub 2006 Aug 9.

PMID:
16901468
2.

Clioquinol and docosahexaenoic acid act synergistically to kill tumor cells.

Ding WQ, Liu B, Vaught JL, Palmiter RD, Lind SE.

Mol Cancer Ther. 2006 Jul;5(7):1864-72.

3.

A soluble tissue factor-annexin V chimeric protein has both procoagulant and anticoagulant properties.

Huang X, Ding WQ, Vaught JL, Wolf RF, Morrissey JH, Harrison RG, Lind SE.

Blood. 2006 Feb 1;107(3):980-6. Epub 2005 Sep 29.

4.

Anticancer activity of the antibiotic clioquinol.

Ding WQ, Liu B, Vaught JL, Yamauchi H, Lind SE.

Cancer Res. 2005 Apr 15;65(8):3389-95.

6.
7.

CEP-1347/KT-7515, an inhibitor of SAPK/JNK pathway activation, promotes survival and blocks multiple events associated with Abeta-induced cortical neuron apoptosis.

Bozyczko-Coyne D, O'Kane TM, Wu ZL, Dobrzanski P, Murthy S, Vaught JL, Scott RW.

J Neurochem. 2001 May;77(3):849-63.

8.

Cep-1347 (KT7515), a semisynthetic inhibitor of the mixed lineage kinase family.

Maroney AC, Finn JP, Connors TJ, Durkin JT, Angeles T, Gessner G, Xu Z, Meyer SL, Savage MJ, Greene LA, Scott RW, Vaught JL.

J Biol Chem. 2001 Jul 6;276(27):25302-8. Epub 2001 Apr 26.

9.

CEP-1347 increases ChAT activity in culture and promotes cholinergic neurone survival following fimbria-fornix lesion.

Harper SJ, Saporito MS, Hewson L, Young L, Smith D, Rigby M, Jackson P, Curtis N, Swain C, Hefti F, Vaught JL, Sirinathsinghji D.

Neuroreport. 2000 Jul 14;11(10):2271-6.

PMID:
10923684
10.

Preservation of cholinergic activity and prevention of neuron death by CEP-1347/KT-7515 following excitotoxic injury of the nucleus basalis magnocellularis.

Saporito MS, Brown ER, Carswell S, DiCamillo AM, Miller MS, Murakata C, Neff NT, Vaught JL, Haun FA.

Neuroscience. 1998 Sep;86(2):461-72.

PMID:
9881861
11.

Cell cycle-independent death of prostate adenocarcinoma is induced by the trk tyrosine kinase inhibitor CEP-751 (KT6587).

Dionne CA, Camoratto AM, Jani JP, Emerson E, Neff N, Vaught JL, Murakata C, Djakiew D, Lamb J, Bova S, George D, Isaacs JT.

Clin Cancer Res. 1998 Aug;4(8):1887-98.

12.

Orally active benzamide antipsychotic agents with affinity for dopamine D2, serotonin 5-HT1A, and adrenergic alpha1 receptors.

Reitz AB, Baxter EW, Codd EE, Davis CB, Jordan AD, Maryanoff BE, Maryanoff CA, McDonnell ME, Powell ET, Renzi MJ, Schott MR, Scott MK, Shank RP, Vaught JL.

J Med Chem. 1998 Jun 4;41(12):1997-2009.

PMID:
9622541
13.

CEP-1347/KT7515 prevents motor neuronal programmed cell death and injury-induced dedifferentiation in vivo.

Glicksman MA, Chiu AY, Dionne CA, Harty M, Kaneko M, Murakata C, Oppenheim RW, Prevette D, Sengelaub DR, Vaught JL, Neff NT.

J Neurobiol. 1998 Jun 15;35(4):361-70.

PMID:
9624618
14.

Structure-activity studies on anticonvulsant sugar sulfamates related to topiramate. Enhanced potency with cyclic sulfate derivatives.

Maryanoff BE, Costanzo MJ, Nortey SO, Greco MN, Shank RP, Schupsky JJ, Ortegon MP, Vaught JL.

J Med Chem. 1998 Apr 9;41(8):1315-43. Erratum in: J Med Chem. 2003 Feb 13;46(4):652..

PMID:
9548821
15.

Insulin-like growth factor-I prevents development of a vincristine neuropathy in mice.

Contreras PC, Vaught JL, Gruner JA, Brosnan C, Steffler C, Arezzo JC, Lewis ME, Kessler JA, Apfel SC.

Brain Res. 1997 Nov 7;774(1-2):20-6.

PMID:
9452187
16.

CEP-751 inhibits TRK receptor tyrosine kinase activity in vitro exhibits anti-tumor activity.

Camoratto AM, Jani JP, Angeles TS, Maroney AC, Sanders CY, Murakata C, Neff NT, Vaught JL, Isaacs JT, Dionne CA.

Int J Cancer. 1997 Aug 7;72(4):673-9.

17.

Neurotrophic 3,9-bis[(alkylthio)methyl]-and-bis(alkoxymethyl)-K-252a derivatives.

Kaneko M, Saito Y, Saito H, Matsumoto T, Matsuda Y, Vaught JL, Dionne CA, Angeles TS, Glicksman MA, Neff NT, Rotella DP, Kauer JC, Mallamo JP, Hudkins RL, Murakata C.

J Med Chem. 1997 Jun 6;40(12):1863-9.

PMID:
9191963
18.

Aroyl(aminoacyl)pyrroles, a new class of anticonvulsant agents.

Carson JR, Carmosin RJ, Pitis PM, Vaught JL, Almond HR, Stables JP, Wolf HH, Swinyard EA, White HS.

J Med Chem. 1997 May 23;40(11):1578-84.

PMID:
9171868
19.

Potential utility of rhIGF-1 in neuromuscular and/or degenerative disease.

Vaught JL, Contreras PC, Glicksman MA, Neff NT.

Ciba Found Symp. 1996;196:18-27; discussion 27-38.

PMID:
8866126
20.

Systemic administration of rhIGF-I enhanced regeneration after sciatic nerve crush in mice.

Contreras PC, Steffler C, Yu E, Callison K, Stong D, Vaught JL.

J Pharmacol Exp Ther. 1995 Sep;274(3):1443-9.

PMID:
7562520
21.

Beneficial effects of insulin-like growth factor-I on wobbler mouse motoneuron disease.

Hantaï D, Akaaboune M, Lagord C, Murawsky M, Houenou LJ, Festoff BW, Vaught JL, Rieger F, Blondet B.

J Neurol Sci. 1995 May;129 Suppl:122-6.

PMID:
7595602
22.

A new arylpiperazine antipsychotic with high D2/D3/5-HT1A/alpha 1A-adrenergic affinity and a low potential for extrapyramidal effects.

Reitz AB, Bennett DJ, Blum PS, Codd EE, Maryanoff CA, Ortegon ME, Renzi MJ, Scott MK, Shank RP, Vaught JL.

J Med Chem. 1994 Apr 15;37(8):1060-2. No abstract available.

PMID:
7909336
23.

Topiramate: preclinical evaluation of structurally novel anticonvulsant.

Shank RP, Gardocki JF, Vaught JL, Davis CB, Schupsky JJ, Raffa RB, Dodgson SJ, Nortey SO, Maryanoff BE.

Epilepsia. 1994 Mar-Apr;35(2):450-60.

PMID:
8156972
24.

Systemic dexamethasone administration increases septal Trk autophosphorylation in adult rats via an induction of nerve growth factor.

Saporito MS, Brown ER, Hartpence KC, Wilcox HM, Robbins E, Vaught JL, Carswell S.

Mol Pharmacol. 1994 Mar;45(3):395-401.

PMID:
8145726
25.

Chronic 1,25-dihydroxyvitamin D3-mediated induction of nerve growth factor mRNA and protein in L929 fibroblasts and in adult rat brain.

Saporito MS, Brown ER, Hartpence KC, Wilcox HM, Vaught JL, Carswell S.

Brain Res. 1994 Jan 7;633(1-2):189-96.

PMID:
8137156
26.

Insulin-like growth factor-I: potential for treatment of motor neuronal disorders.

Lewis ME, Neff NT, Contreras PC, Stong DB, Oppenheim RW, Grebow PE, Vaught JL.

Exp Neurol. 1993 Nov;124(1):73-88. Review.

PMID:
8282084
27.

Pharmacological induction of nerve growth factor mRNA in adult rat brain.

Saporito MS, Wilcox HM, Hartpence KC, Lewis ME, Vaught JL, Carswell S.

Exp Neurol. 1993 Oct;123(2):295-302.

PMID:
8405292
28.

Complementary and synergistic antinociceptive interaction between the enantiomers of tramadol.

Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL, Jacoby HI, Selve N.

J Pharmacol Exp Ther. 1993 Oct;267(1):331-40.

PMID:
8229760
29.

rhIGF-I enhances functional recovery from sciatic crush. Time-course and dose-response study.

Contreras PC, Steffler C, Vaught JL.

Ann N Y Acad Sci. 1993 Aug 27;692:314-6. No abstract available.

PMID:
8215040
30.

The potential of insulin-like growth factor-I as a therapeutic for the treatment of neuromuscular disorders.

Lewis ME, Vaught JL, Neff NT, Grebow PE, Callison KV, Yu E, Contreras PC, Baldino F Jr.

Ann N Y Acad Sci. 1993 Aug 27;692:201-8. Review. No abstract available.

PMID:
8215023
31.

Aurintricarboxylic acid protects hippocampal neurons from NMDA- and ischemia-induced toxicity in vivo.

Roberts-Lewis JM, Marcy VR, Zhao Y, Vaught JL, Siman R, Lewis ME.

J Neurochem. 1993 Jul;61(1):378-81.

PMID:
8515286
32.

The combined immunological and antinociceptive defects of beige-J mice: the possible existence of a 'mu-repressin'.

Raffa RB, Mathiasen JR, Kimball ES, Vaught JL.

Life Sci. 1993;52(1):1-8. Review.

PMID:
8380213
33.

Deposition of beta/A4 immunoreactivity and neuronal pathology in transgenic mice expressing the carboxyl-terminal fragment of the Alzheimer amyloid precursor in the brain.

Kammesheidt A, Boyce FM, Spanoyannis AF, Cummings BJ, Ortegón M, Cotman C, Vaught JL, Neve RL.

Proc Natl Acad Sci U S A. 1992 Nov 15;89(22):10857-61.

34.

2-Substituted 1-azabicycloalkanes, a new class of non-opiate antinociceptive agents.

Carson JR, Carmosin RJ, Vaught JL, Gardocki JF, Costanzo MJ, Raffa RB, Almond HR Jr.

J Med Chem. 1992 Jul 24;35(15):2855-63.

PMID:
1495016
35.

Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity.

Raffa RB, Shank RP, Vaught JL.

Psychopharmacology (Berl). 1992;108(3):320-6.

PMID:
1387963
36.

Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an 'atypical' opioid analgesic.

Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL.

J Pharmacol Exp Ther. 1992 Jan;260(1):275-85.

PMID:
1309873
38.

The novel anticonvulsant loreclezole (R 72063) does not produce diazepam-like anterograde amnesia in a passive avoidance test in rats.

Raffa RB, Vaught JL, Setler PE.

Naunyn Schmiedebergs Arch Pharmacol. 1990 Nov;342(5):613-5.

PMID:
2090955
39.

Pyrroloisoquinoline antidepressants. 3. A focus on serotonin.

Maryanoff BE, Vaught JL, Shank RP, McComsey DF, Costanzo MJ, Nortey SO.

J Med Chem. 1990 Oct;33(10):2793-7.

PMID:
2213832
40.

Antinociceptive action of McN-5195 in rodents: a structurally novel (indolizine) analgesic with a nonopioid mechanism of action.

Vaught JL, Carson JR, Carmosin RJ, Blum PS, Persico FJ, Hageman WE, Shank RP, Raffa RB.

J Pharmacol Exp Ther. 1990 Oct;255(1):1-10.

PMID:
2170621
41.
42.

Can equal pA2 values be compatible with receptor differences?

Raffa RB, Vaught JL, Porreca F.

Trends Pharmacol Sci. 1989 May;10(5):183-5. Review.

PMID:
2667226
43.

McN-5652: a highly potent inhibitor of serotonin uptake.

Shank RP, Vaught JL, Pelley KA, Setler PE, McComsey DF, Maryanoff BE.

J Pharmacol Exp Ther. 1988 Dec;247(3):1032-8.

PMID:
2905001
44.
45.

Interactions of substance P antagonists with serotonin in the mouse spinal cord.

Vaught JL, Scott R.

Peptides. 1988 Jul-Aug;9(4):909-13.

PMID:
2465543
46.

[3H][D-Ala2,NMePhe4,Gly-ol5]-enkephalin (mu-opioid) binding in beige-J mice.

Raffa RB, Baldy WJ Jr, Shank RP, Mathiasen JR, Vaught JL.

Peptides. 1988 May-Jun;9(3):637-42.

PMID:
2843835
47.

Can supraspinal delta-opioid receptors mediate antinociception?

Heyman JS, Vaught JL, Raffa RB, Porreca F.

Trends Pharmacol Sci. 1988 Apr;9(4):134-8. Review. No abstract available.

PMID:
2854316
48.
49.

Neurokinin-induced generation of interleukin-1 in a macrophage cell line.

Kimball ES, Persico FJ, Vaught JL.

Ann N Y Acad Sci. 1988;540:688-90. No abstract available.

PMID:
2462840
50.

Substance P antagonists and analgesia: a review of the hypothesis.

Vaught JL.

Life Sci. 1988;43(18):1419-31. Review.

PMID:
2460712

Supplemental Content

Loading ...
Support Center